Overexpression of MicroRNA-200c Predicts Poor Outcome in Patients with PR-Negative Breast Cancer

Marie Tuomarila1, Kaisa Luostari1, Ylermi Soini1, Vesa Kataja2, Veli-Matti Kosma1,*, Arto Mannermaa1,*,†

1 Institute of Clinical Medicine, Clinical Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland, 2 Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland

Abstract

Micro-RNAs are small, noncoding RNAs that act as tumor suppressors or oncogenes. MiR-200c is a member of the miR-200 family; it is known to be dysregulated in invasive breast carcinoma. MiR-200c maintains the epithelial-mesenchymal transition and inhibits cell migration and invasion. Recent studies showed that miR-200c regulated steroid hormone receptors, estrogen receptors (ER), and progesterone receptors (PR). The present study aimed to detect miR-200c in 172 invasive breast carcinoma cases selected from a prospective cohort enrolled in Kuopio, Eastern Finland, between 1990 and 1995. MiR-200c expression was determined with relative q-PCR, and results were compared to clinicopathological variables and patient outcome. We found that PR status combined with miR-200c expression was a significant marker of outcome. High miR-200c expression was associated with reduced survival in PR-negative cases (n = 68); low miR-200c expression indicated reduced survival in PR-positive cases (n = 86) (Cox regression: P = 0.002, OR = 3.433; and P = 0.004, OR = 4.176, respectively). In PR-negative cases, high miR-200c expression was associated with shortened relapse-free survival (Cox regression: P = 0.001, OR = 3.613; increased local/distant recurrence (Logistic regression: P = 0.006, OR = 3.965); and more frequent distant metastasis (Logistic regression: P = 0.015, OR = 3.390). We also found that high grade and low stage tumors were positively correlated with high miR-200c expression (Logistic regression for high grade tumors: P = 0.002, OR = 2.791 and for high stage tumors: P = 0.035, OR = 0.285). Our results indicated that miR-200c may play a role in invasive breast carcinoma. Furthermore, miR-200c combined with PR status provided a refined predictor of outcome. In future, a larger study is required to confirm our results. This data may provide a basis for new research target–progesterone receptor–regulated microRNAs in breast cancer.

Introduction

Breast cancer is a heterogeneous disease with subtypes characterized by many different biological and clinical features. The disease prognosis varies with the subtype and other clinical markers [1–3]. Immunohistochemical studies are routinely conducted to detect molecular markers that identify different subtypes. These markers include the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2), and Ki-67 labeling index. The detection of these markers facilitates diagnosing and planning the appropriate therapy [4]. Nevertheless, novel diagnostic methods and better factors for predicting risk are needed to extend our understanding of breast cancer and to develop new therapeutic methods for combating cancer.

Hormonal functions in breast cancer and normal breast tissue have been widely studied. Evidence emphasizes the role of both estrogen and progesterone steroid hormones in the initiation and growth of breast tumors. The actions of progesterone and estrogen in breast cancer are mediated by their cognate receptors, PR and ER, respectively. Recent studies have suggested that there may be a link between deregulated microRNAs (miRNAs) and steroid hormones in malignancies [3,6].

miRNAs are small, non-coding RNAs, approximately 19–24 nucleotides long, which bind specifically to the 3′-untranslated regions (3′-UTRs) of target miRNAs and regulate their translation to proteins [7]. In recent years, studies have revealed an association between the differential expression of microRNAs and cancerous tissues. The miRNAs involved in cancer may act as tumor suppressors or oncogenes, depending on the target [8–10].

The miR-200 family includes the mature miR-200c, miR-141, miR-200b, miR-200a, and miR-429 [11]. These miRNAs have been shown to maintain the epithelial phenotype in breast cancer; to inhibit cell migration and invasion by targeting epithelial-mesenchymal transition (EMT) repressors and transcriptional factors ZEB1 and ZEB2 [12–15]; to suppress the genes involved in...
MicroRNA-200c Predicts Outcome in PR-Negative Breast Cancer Cases

Materials and Methods

Materials

There were a total of 172 invasive breast cancer cases available for the present study. The material was unselected and no power calculations were conducted. The case records and samples were acquired from the Kuopio Breast Cancer Project (KBCP), which was conducted from April 1990 to December 1995. More detailed information about the samples and clinical features of the patients in the KBCP was published previously [32,33].

In this study, the mean age of the 172 patients at the time of diagnosis was 60.4 years. At the cut-off point in February 2011, the average follow-up time was 9.7 years, with a range of 0.10 to 19.8 years. Sixty patients had died of breast cancer during the follow-up, 59 died from other reasons, and 53 patients remained alive. The next cut-off point in July 2013 clarified the metastases of the patients; 60 patients had primary distant metastasis, and 30 patients had secondary, tertiary, or quaternary metastases. The next cut-off point in February 2011, the average follow-up time was 60.4 years. At the cut-off point in February 2011, the average follow-up time was 9.7 years, with a range of 0.10 to 19.8 years. Sixty patients had died of breast cancer during the follow-up, 59 died from other reasons, and 53 patients remained alive. The next cut-off point in July 2013 clarified the metastases of the patients; 60 patients had primary distant metastasis, and 30 patients had secondary, tertiary, or quaternary metastases. The average follow-up time was 9.7 years, with a range of 0.10 to 19.8 years.

This study was approved by the Joint Ethics Committee of the University of Kuopio/University of Eastern Finland and the Kuopio University Hospital (written consents 1/1989 and 61/2010). Each patient gave informed written consent for participation in the study.

Nucleic Acid Isolation and real-time qRT-PCR

RNA was extracted from fresh-frozen tissues stored at −70°C with the MirVana miRNA Isolation Kit (Ambion, Austin, Texas, TX). Approximately 30 mg of fresh frozen tissue was taken and total RNA was isolated according to the manufacturer’s protocol.

Complementary DNA (cDNA) was synthesized from 10 ng of total RNA by reverse transcription with the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, Grand Islands, NY) using gene-specific primers for hsa-miR-200c (ID 002300) and RNU48 (ID 001006), according to the manufacturer’s instructions. We evaluated miRNA levels with TaqMan MicroRNA Assay for miR-200c (ID 002300) and RNU48 (ID 001006) with qRT-PCR following the protocol provided by the manufacturer. The reactions were carried on a Mx3000 Real-Time PCR System (Life Technologies, Grand Islands, NY). The RNU48 primer was used to produce the endogenous control, based on the manufacturer’s recommendations. The standard curves for both miR-200c and RNU48 were generated and used for validation. The relative gene expression values were calculated according to the ΔΔCt method, where the mean threshold cycle value (Ct) for three replicates was used for each sample. The relative expression values (fold change) can be seen in table S2.

Then, the miR-200c expression levels observed in different samples were assigned to one of two groups for further analyses: (1) the moderate/high expression group comprised samples with expression levels greater than median miR-200c level; (2) the low expression group comprised samples with expression levels lower than the median miR-200c level.

Statistical analysis

The statistical analyses were performed with SPSS for Windows, version 19.0 (SPSS Inc., Chicago, IL, USA). The chi-squared test and the logistic regression analysis were used to compare the miR-200c expression levels among different groups and to determine the association between miRNA-200c expression and clinical variables. Survival rates were evaluated with the Kaplan-Meier method. We used the log-rank, Breslow and Tarone-Ware test, with death due to breast cancer as the end point. To study the association between miR-200c expression and breast cancer survival, Cox regression was used in a multivariate analysis. P-values less than 0.05 were considered statistically significant.

Results

High miR-200c expression correlates with grade 3 tumors

First, the relative miR-200c expression rates were compared with the clinicopathological variables of the 172 invasive breast carcinoma samples. Notably, high miR-200c expression was associated with grade 3 tumors (P = 0.002, Table 1) and with low stage cancers (P = 0.045, Table 1).

Low miR-200c expression in PR-positive cases is independently associated with poor survival

When only the patients with PR-positive tumors (n = 94) were evaluated with the Kaplan-Meier analysis, low miR-200c expression appeared to predict poor breast cancer specific survival (P = 0.003, Figure 1A). Multivariate analysis also showed that low miR-200c expression was an independent factor for predicting poor survival (Figure 1B), in addition to nodal status and Her2-status, (P = 0.004, OR = 4.176, table S3). The same association was found in both PR and ER positive cancers (n = 88) in Kaplan-Meier analysis (P = 0.013, figure S1).

High miR-200c expression in the PR-negative cases predicts poor survival and a short relapse-free survival

When patients with PR-negative tumors (n = 72) were evaluated with the Kaplan-Meier analysis, high miR-200c expression appeared to be associated with poor breast cancer specific survival (P = 0.002, Figure 2A). The same result was obtained in the multivariate analysis (P = 0.002, OR = 3.433, Figure 2B). In
addition, the histological type, ER status, and tumor size were significantly related to survival (table S4).

Of the 72 PR-negative cases, 45 were both PR-negative and ER-negative. To investigate whether the ER status affected the results, the Kaplan-Meier survival analysis was applied to cases with both PR-negativity and ER-negativity. We found that high miR-200c expression remained associated with poor survival in this group (\(P = 0.025\), figure S2). Interestingly, the Cox analysis did not show a significant association between miR-200c and

### Table 1. Clinical characteristics associated with miR-200c expression in patients with breast cancer.

| Clinical variable          | miR-200c expression\(^a\) | \(P\) | OR (95% CL)       |
|---------------------------|---------------------------|------|-------------------|
| **Clinical variable**     | n                         | Low expression (%) | High expression (%) |      |
| Age at diagnosis          |                           |                  |                   |      |
| \(< = 59\)                | 85                        | 38 (22.1)         | 47 (27.3)          | 0.17\(^b\) |
| \(> = 60\)               | 87                        | 48 (27.9)         | 39 (22.7)          |      |
| Patient status            |                           |                  |                   |      |
| Dead, breast cancer       | 60                        | 29 (16.9)         | 31 (18.0)          | 0.242\(^b\) |
| Dead, other cause         | 59                        | 35 (20.3)         | 24 (14.0)          |      |
| Alive, no recurrence      | 46                        | 20 (11.6)         | 26 (15.1)          |      |
| Alive, recurrence         | 7                         | 2 (1.2)           | 5 (2.9)            |      |
| Histological grade        |                           |                  |                   |      |
| I and II                  | 106                       | 63 (37.8)         | 43 (27.5)          | 0.002 |
| III                       | 61                        | 21 (12.6)         | 40 (24.0)          | 2.79 (1.45–5.37) |
| Histological stage        |                           |                  |                   |      |
| I                         | 44                        | 21 (12.7)         | 23 (13.9)          | 0.045 |
| II                        | 100                       | 45 (27.2)         | 55 (33.3)          | 0.762 |
| III and IV                | 21                        | 16 (9.7)          | 5 (3.0)            | 0.035 |
| Histological type         |                           |                  |                   |      |
| Ductal                    | 117                       | 54 (32.3)         | 63 (37.7)          | 0.254\(^b\) |
| Lobular                   | 31                        | 19 (11.4)         | 12 (7.2)           |      |
| Other                     | 19                        | 11 (6.6)          | 8 (4.8)            |      |
| Estrogen receptor         |                           |                  |                   |      |
| Negative                  | 51                        | 26 (15.7)         | 25 (15.0)          | 0.866\(^b\) |
| Positive                  | 115                       | 57 (34.3)         | 58 (34.9)          |      |
| Progesterone receptor     |                           |                  |                   |      |
| Negative                  | 72                        | 40 (24.1)         | 32 (19.3)          | 0.21\(^b\) |
| Positive                  | 94                        | 43 (25.9)         | 51 (30.7)          |      |
| Her2-status               |                           |                  |                   |      |
| Negative                  | 133                       | 67 (42.1)         | 66 (41.5)          | 0.452\(^b\) |
| Positive                  | 26                        | 11 (6.9)          | 15 (9.4)           |      |
| Triple negativity         |                           |                  |                   |      |
| Yes                       | 29                        | 16 (9.3)          | 13 (7.6)           | 0.541\(^b\) |
| No                        | 143                       | 70 (40.7)         | 73 (42.4)          |      |
| Local/distant recurrence  |                           |                  |                   |      |
| Yes                       | 73                        | 32 (18.7)         | 41 (24.0)          | 0.185\(^b\) |
| No                        | 98                        | 53 (31.0)         | 45 (26.3)          |      |
| Primary distant metastasis|                           |                  |                   |      |
| Yes                       | 60                        | 27 (15.7)         | 33 (19.2)          | 0.337\(^b\) |
| No                        | 112                       | 59 (34.3)         | 53 (30.8)          |      |
| Luminal type A/B          |                           |                  |                   |      |
| Luminal A (er\(^+\), Her2\(^−\), pr\(^+\)) | 100 | 49 (49.4) | 51 (47.2) | 0.531\(^b\) |
| Luminal B (er\(^+\), Her2\(^+\), pr\(^−\)) | 8  | 3 (2.8) | 5 (46.3) |

Abbreviations: n, number of cases; Ref, reference category in the logistic regression analysis.

\(^a\)Low and high relative expression of miR-200c according to the median value.

\(^b\)\(P\) value assessed by chi-square test; other \(P\) values based on the logistic regression analysis.

doi:10.1371/journal.pone.0109508.t001
survival in the group with both ER – and PR – negative cancer in contrast to the Cox analysis of only PR – negative tumors.

Next, we investigated whether miR-200c expression was associated with relapse-free-survival with the Kaplan-Meyer analysis. In the PR-negative group, patients with high miR-200c expression showed poor relapse-free survival in the 20-year follow-up compared to those with low miR-200c (P = 0.001, Figure 3A). The same result was obtained in the Cox regression analysis (P = 0.001, OR = 3.613, Figure 3B, table S5).

Figure 1. MiR-200c expression and breast cancer specific survival in PR – positive cancer cases. A) Kaplan-Meier analysis; B) Cox regression analysis including covariates age at diagnosis, nodal status, size of the tumor, histological type, Her2-status, and ER-status. OR (95% CI), OR of breast cancer specific death with 95% CI in multivariate analysis.
doi:10.1371/journal.pone.0109508.g001

Figure 2. MiR-200c expression and breast cancer specific survival in PR – negative cancer cases. A) Kaplan-Meier analysis; B) Cox regression analysis including covariates age at diagnosis, nodal status, size of the tumor, histological type, Her2-status, and ER-status. OR (95% CI), OR of breast cancer specific death with 95% CI in multivariate analysis.
doi:10.1371/journal.pone.0109508.g002
We also examined whether the miR-200c expression was related to local/distant recurrence of breast cancer. Among the PR-negative cases, we compared the miR-200c expression levels in patients with and without local/distant recurrence. The PR-negative cases \((n = 72)\) with local or distant recurrence had higher miR-200c expression levels than those without recurrence \((P = 0.006, \text{OR} = 3.965)\).

We then studied whether miR-200c expression was related to distant metastasis of breast carcinoma. Among the PR-negative cases, we compared the miR-200c expression levels in patients with and without distant metastasis. We found that cases with distant metastasis had higher miR-200c expression than cases without metastasis \((n = 72, P = 0.015, \text{OR} = 3.390)\).

**Discussion**

This study is the first to link breast cancer survival to miR-200c expression levels and PR status. Our data suggests that the PR status of the tumor influences whether miR-200c expression affects patient survival. We found that high miR-200c expression is an independent factor for predicting poor survival in the group of patients with PR-negative tumors. In contrast, we found that low miR-200c expression is an independent factor for predicting poor survival in the group of patients with PR-positive tumors. The same association was found in patients with tumors positive for both ER and PR. Among the PR-negative cases, high miR-200c expression was also associated with short recurrence-free survival. Among patients with PR-negative tumors, those that experienced local/distant recurrence had higher levels of miR-200c than the patients without recurrences. Similarly, among patients with PR-negative tumors, those that experienced distant metastases had higher miR-200c expression rates than the patients without metastases. These findings may facilitate the future diagnosis and management of patients with breast cancer.

ERs and PRs are key elements in breast cancer tumorigenesis, but microRNAs represent a relatively new chapter in the clinical setting of molecular laboratory research. Rather small number of studies has been published on the miR-200 family in connection with breast cancer and PR. Recently, the interactions between hormone receptors and miRNAs were found to contribute to breast cancer disease progression [34]. Several studies have shown that ER regulates miRNAs, but only a few studies have identified PR-regulated miRNAs. The connection between PR and miRNAs was first discovered in the genital tissue of women [35–39]. In another study, PR was found to regulate miRNAs in breast cancer. They showed that miR-16 and other miRNAs were down- or upregulated through synthetic progestin medroxyprogesterone acetate in breast cancer cell lines, but miR-200c was not one of them [27]. Further, as a response to progestin treatment, regulation of MiR-200c was altered in MCF10A cells [28] and a member of miR-200 family, miRNA-141 downregulated in T47D cells [30]. Again, PR expression was regulated by a progesterin-upregulated miR-513a-3p [30] and progestins downregulated miR-29 in hormone receptor -positive breast cancer [31]. Also, PR-specific miRNAs have been identified. ER-specific downregulation of miR-181 and miR-26a targeting the 3’UTR of the PR sequence led to upregulation of the PR gene [29].

In the present study, it is possible that the PR modulated miR-200c expression. Indeed, miR-200c behaved differently in PR-negative and PR-positive cancers when analyzing the outcome of the patients. However, we did not observe significant differences in miR-200c expression levels between PR-negative and PR-positive cases in Kruskal-Wallis test when analyzing the status at the time of the diagnosis.

The PR is also regulated by estrogen, and the PR and ER tend to act in a consistent manner in breast cancer [40,41]. In the present study, of the 94 PR-positive cases, 86 were also ER-positive. Nevertheless, when we included only the ER-positive cases in the calculations, no correlation was found between miR-
200c expression and survival, despite the large number of patients and a relatively high rate of death from breast cancer ($P = 0.259$). Similarly, although the ER-negative group comprised fewer patients, they also showed no correlation between miR-200c expression and survival.

Nodal status is often one of the strongest predictors of the patient survival. The presence of nodes positive for cancer (node positivity) was statistically significant in the PR-positive group, when assessed with the multivariate analysis. However, in the PR-negative group, the Cox regression did not show significant node positivity in contrast to tumor size, histological type and ER status. This difference may have been due to the smaller number of samples with positive nodes in the PR-negative group, compared to that in the PR-positive group. On the other hand, PR positive tumors tend to be also ER positive that have a specific and efficient treatment. In these cases noda status is often a strong prognostic factor. One might speculate that patients with PR negative cancers lacking an efficient treatment often have a poor prognosis and then nodal status would be of no relevance.

Previously, two studies have reported findings in line with those of the present study. [42,43]. They also suggested that PR-status was a key factor in distinguishing among breast cancer subtypes. PR-positivity alone could predict whether patients with ER-positive breast cancer had a high risk (luminal B) or low risk (luminal A) prognosis [42,43]. Notably, those studies did not include miR-200c expression. We did not compare outcomes between ER-positive cases with or without PR-positivity, because there were only a few ER-positive cases with PR-negativity. We found that the group with both ER-positivity and PR-positivity had the same outcome as the group with only PR-positivity. Our results indicated that, in addition to the PR status, the miR-200c expression level played a role in the subtype classification. Gene expression profiling studies have identified four significantly different classes of breast cancer, known as luminal A, luminal B, basal-like, and Her2-status positive [1,2]. Our study included only 8 patients with luminal B class tumors and 100 patients with luminal A class tumors. We found no correlation between the miR-200c expression level and the luminal class. However, PR status was significantly associated to the outcome. Our study also included 29 triple negative cases, tumors negative for ER, PR and Her2-status, but no association with miR-200c expression among the cases was found. Therefore, a larger sample set that includes triple negative cancers is required for more accurate calculations.

Altered expressions of miRNAs have lately been linked with outcome of the cancer patients. High levels of miR-221 and miR-21 expression were associated with a poor prognosis in hepatocellular carcinoma [44], and high levels of miR-21 and miR-200c expression were associated with a poor survival in non-small-cell lung carcinoma [45]. In epithelial ovarian cancer, miR-200c expression was a potential predictor of survival and a biomarker for relapse [46]. In ovarian cancer, low miR-429 was associated with poor progression-free survival [47]. In pancreatic cancer, patients with high miR-200c levels displayed better survival than those with low miR-200c levels [48]. High miR-205 expression was linked to poor survival in endometrial cancer [49].

To our knowledge, miR-200c has not been previously linked to survival in breast cancer. However, it is plausible that low levels of miR-200c, which increase migration and invasion, might lead to poor survival. This hypothesis was consistent with our findings in the PR-positive group, but it was contradicted by our findings in the PR-negative group. Most previous studies have focused on ER-positive and PR-negative tumors. Although it would be interesting to study ER-negative and PR-positive tumors, it may be difficult, due to their rare occurrence.

Our results also underlined the effects of miR-200c expression and PR on recurrence-free survival. In the PR-negative group, patients with high miR-200c expression showed a shorter time to relapse than those with low miR-200c expression. This result was consistent with our finding that PR-negative cases had a worse outcome with high miR-200c expression than with low miR-200c expression. To our knowledge, this study was the first to link miR-200c expression to relapse rates in breast cancer.

Metaplastic breast cancers [14,22] and claudin-low breast cancers [22] show reduced expression of the miR-200 family. In a study by Castilla et al., ER-positive tumors expressed high levels of miR-200 family and Her2-status positive, and triple negative tumors expressed intermediate levels of miR-200 family [22]. Our results differed from those of Castilla et al., possibly due to the small number of samples in our study for Her2-status positive and triple negative tumors. Cochrane et al. reported high levels of miR-200c in well-differentiated breast cell lines, but very low levels in poorly-differentiated cell lines [50]. In contrast to those results, we found an association between high miR-200c levels and poorly-differentiated grade 3 tumors, and this association remained significant after adjusting for PR status ($P = 0.001$ and $P = 0.015$ for PR positive cases and PR negative cases, respectively). However, it has to be taken into account that our material consisted of tumor samples that are more heterogeneous than cancer cell lines. Bockmeyer et al. postulated that miR-200c and miR-429 were downregulated only in malignant myoepitheliomas, but not in basal-like breast cancers [51]. They suggested that high expression of miR-200c and miR-429 stabilized the epithelial phenotype and prevented invasive cell growth. Our findings of high miR-200c expression in grade 3 tumors contradicted Bockmeyer’s findings. The discrepancies between our results and Bockmeyer’s might be explained by differences in tumor samples. In general, patients with distant metastasis have a worse outcome than patients with no metastases. However, miR-200c was found to be overexpressed in distant metastasis compared to its expression in the primary tumor [52]. Our data showed high miR-200c expression in PR-negative tumors with patients that have distant metastasis and with grade 3 patients in the whole material and in the PR negative patients. Although our results were originated in primary tumors these results are to some extend in line with the study of Gravgaard et al. It would be tempting to speculate that miR-200c expression increases during breast cancer progression and that it might be involved in metastatic process. However, we could not find further evidence when comparing miR-200c expression with tumor stage.

The transcriptional factors, ZEB1 and ZEB2 were previously demonstrated to be regulated by miR-200c, and they were found to be reciprocally expressed in breast cancer [12–14,33]. We investigated the relationship between miR-200c and ZEB1, but found no correlation (data not shown). The data and procedure of the immunohistochemistry for ZEB1 was published previously [54]. However, this discrepancy may be explained by assessment of different phases of gene expression of ZEB1. Also our tumor samples included both malignant and non malignant cells that may differ in miR-200c expression and ZEB1 protein expression. Thus, our results may present expression of miR-200c in the microenvironment of the epithelial tumor rather than only in malignant epithelial cells.

An in silico analysis with Targetscan [55] showed that Cyp1b1 was a target for miR-200c. According to the KEGG pathway platform [56] Cyp1b1 is also involved in steroid hormone biosynthesis. This connection suggested that miR-200c may play a role in steroid hormone biosynthesis at the gene level.
In conclusion, we have demonstrated that high miR-200c expression is an independent factor for predicting outcome for patients with invasive breast cancer. Furthermore, we found that high miR-200c expression was linked to grade 3 tumors. However, the nature of the prediction depended on the PR status of the tumor. In PR-negative tumors, high miR-200c expression was associated with a high probability of relapse, poor survival, and distant metastasis. Thus, increase of miR-200c expression could be a marker of breast cancer progression. Also, these results suggested a novel role for PR in breast cancer. In future, additional research with larger number of clinical samples will assure the role of miR-200c and PR in breast cancer risk, diagnostics and prognosis.

Supporting Information

Figure S1 MiR-200c expression and breast cancer specific survival in PR – and ER – positive cancer cases. (TIF)

Figure S2 Kaplan-Meier analysis of miR-200c expression and breast cancer specific survival in PR - and ER - negative cancer cases. (TIF)

Table S1 Clinical characteristics of the tumor material. Abbreviations: n, number of cases. (DOCX)

Table S2 Relative miR-200c expression values. (DOCX)

Table S3 Multivariate analysis assessments of clinicopathological variables and miR-200c expression in breast cancer specific survival with PR positive cancer cases. Abbreviations: n, number of cases; B coefficient with standard error (SE) from the multivariate analysis; Ref, reference category used for comparison. Note: clinical variables included: age at diagnosis, nodal status, tumor size, histological type, Her2-status and estrogen receptor status. *: Low and high relative expression of miR-200c according to the median value. (DOCX)

Table S4 Multivariate analysis assessments of clinicopathological variables and miR-200c expression in breast cancer specific survival with PR negative cancer cases. Abbreviations: n, number of cases; B coefficient with standard error (SE) from the multivariate analysis; Ref, reference category used for comparison. Note: clinical variables included: age at diagnosis, nodal status, tumor size, histological type, Her2-status and estrogen receptor status. #: Low and high relative expression of miR-200c according to the median value. (DOCX)

Table S5 Multivariate analysis assessments of clinicopathological variables and miR-200c expression in breast cancer recurrence-free survival with PR negative cancer cases. Abbreviations: n, number of cases; B coefficient with standard error (SE) from the multivariate analysis; Ref, reference category used for comparison. Note: clinical variables included: age at diagnosis, nodal status, tumor size, histological type, Her2-status and estrogen receptor status. #: Low and high relative expression of miR-200c according to the median value. (DOCX)

Author Contributions

Conceived and designed the experiments: AM YS V-MK VK. Performed the experiments: MT. Analyzed the data: MT KL AM. Contributed reagents/materials/analysis tools: MT KL AM V-MK YS VK. Contributed to the writing of the manuscript: MT. Revised the manuscript: AM KL YS V-MK VK.

References

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclases with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 11024–11029.
4. Goldhirsh A, Wood WC, Coates AS, Gelber RD, Thurlimann B, et al. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22: 1736–1747.
5. Kliing CM (2009) Estrogen regulation of MicroRNA expression. Curr Genomics 10: 169–183.
6. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, et al. (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/receptor status in breast cancer. Breast Cancer Res 11: R27.
7. Bartel DP (2005) MicroRNAs: Target recognition and regulatory functions. Cell 130: 225–233.
8. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704–714.
9. Galan GA, Dummitt CD, Shinmin M, Iuchi R, Zupko S, et al. (2002) Frequent deletions and down-regulation of micro RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15324–15329.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838.
11. Howe EN, Cochrane DR, Cittelly DM, Richer JK (2012) miR-200c targets a NF-kappaB up-regulated TrkB/NTF3 autocrine signaling loop to enhance NF-kappaB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis resistance in breast cancer cells and breast cancer. J Mammary Gland Biol Neoplasia 15: 213–223.
12. Jurmeister S, Baumann S, Balwierz A, Kilkiguoglu I, Ward A, et al. (2012) MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 32: 633–651.
13. Schickel R, Park SM, Murrman AE, Peter ME (2010) miR-200c regulates induction of apoptosis through CD95 by targeting FADD. Mol Cell 38: 908–915.
14. Wright JA, Richer JK, Goodall GJ (2012) microRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia 15: 213–223.
15. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, et al. (2010) MicroRNA link estrogen receptor alpha status and dicer levels in breast cancer. Horm Cancer 1: 306–319.
16. Carulla MA, Diaz-Martin J, Barrio D, Romero-Perez L, Lopez-Garcia MA, et al. (2012) MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 7:e47709.
17. Adams BD, Furneaux H, White BA (2007) The micro-rubiscocelic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21: 1132–1147.
18. Castellano L, Giamas G, Jocob J, Coombes RC, Lucehue W, et al. (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 106: 15732–15737.
19. Bhutani Nakhchani P, Wang G, Collina NR, Thomson JM, Geistlinger TR, et al. (2009) Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 37: 4805–4816.

MicroRNA-200c Predicts Outcome in PR-Negative Breast Cancer Cases
30. Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, et al. (2012) Progestin expression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF5. Oncogene 32: 2555–64.

31. Pellikainen MJ, Pokela TT, Repponen KM, Kataja VV, Kellokoski JK, et al. (2003) p21WAF1 expression in invasive breast cancer and its association with p53, AP2, cell proliferation, and prognosis. J Clin Pathol 56: 214–220.

32. Hartikainen JM, Tuhkanen H, Kataja V, Dunning AM, Antoniou A, et al. (2010) An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: Three candidate regions found. Cancer Epidemiol Biomarkers Prev 19: 75–80.

33. Marchini S, Cavaliere D, Frucio R, Calura E, Garavaglia D, et al. (2011) Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol 12: 273–285.

34. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polyneoncos G, et al. (2013) Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mod Cancerog 52: 297–303.

35. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, et al. (2012) High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 29: 618–626.

36. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

37. Park SM, Gaur AB, Lengyel E, Peter ME. (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

38. Panda H, Pelakha L, Chiang TD, Luo X, Bukulmez O, et al. (2012) MicroRNA-200a serves a key role in the decline of progesterone receptor expression leading to term and preterm labor. Proc Natl Acad Sci U S A 109: 7529–7534.

39. Rivas MA, Venturini L, Huang WY, Schillaci R, Huang TH, et al. (2012) Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 14: R77.

40. Vares G, Cui X, Wang B, Nakajima T, Nenoi M (2013) Generation of breast cancer stem cells by steroid hormones in irradiated human mammary cell lines. PLOS ONE 8: e77124.

41. Williams KC, Renthal NE, Gerard RD, Mendelson CR (2012) The microRNA (miR)-199a/214 cluster mediates opposing effects of progesterone and estrogen on uterine contractility during pregnancy and labor. Mol Endocrinol 26: 1857–1867.

42. Williams KC, Renthal NE, Condron JC, Gerard RD, Mendelson CR (2012) MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proc Natl Acad Sci U S A 109: 7329–7334.

43. Williams KC, Renthal NE, Condron JC, Gerard RD, Mendelson CR (2012) MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proc Natl Acad Sci U S A 109: 7329–7334.

44. Williams KC, Renthal NE, Condron JC, Gerard RD, Mendelson CR (2012) MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proc Natl Acad Sci U S A 109: 7329–7334.

45. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, et al. (2012) High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 29: 618–626.

46. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

47. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

48. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

49. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

50. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

51. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.

52. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family of microRNAs as mediators of progesterone receptor action in breast cancer. Mol Cell Endocrinol 335: 15–25.